Mandate

Vinge has advised Alder on the establishment of Alder III

May 27, 2024 Private Funds

Vinge has advised Alder on the establishment of Alder's third and largest fund to date, Alder III.

Alder has successfully raised approximately SEK 3.1bn in investment commitments from an international investor base, doubling the total investor commitments as compared to its predecessor fund Alder II.

Alder closed its first fund in 2010 and focuses on investing in sustainable technology companies with profitable growth and a turnover of between SEK 100 and 750 million. Alder primarily invests as a majority shareholder in companies established in the Nordic region but may also invest selectively in the rest of Europe. Alder's funds - including Alder III - are classified as so-called Article 9 funds under the SFDR.

Vinge's team primarily consisted of Johan Larsson, Mattias Schömer, Martin Cronsioe, Viveka Classon, Nils Unckel, Ulf Nilsson, Emelie Svanberg, Anton Sjökvist, Semir Omerbasic, Tobias Onegård Karlsson, Marcus Andersson, Viktoria Wnuk, Emelie Zingmark, Helena Göransson,Kamyar Najmi and Nour Makie.

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026